MX2022002139A - Ube3a para el tratamiento del sindrome de angelman. - Google Patents

Ube3a para el tratamiento del sindrome de angelman.

Info

Publication number
MX2022002139A
MX2022002139A MX2022002139A MX2022002139A MX2022002139A MX 2022002139 A MX2022002139 A MX 2022002139A MX 2022002139 A MX2022002139 A MX 2022002139A MX 2022002139 A MX2022002139 A MX 2022002139A MX 2022002139 A MX2022002139 A MX 2022002139A
Authority
MX
Mexico
Prior art keywords
angelman syndrome
ube3a
treatment
polynucleotides
kits
Prior art date
Application number
MX2022002139A
Other languages
English (en)
Inventor
Joseph Anderson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2022002139A publication Critical patent/MX2022002139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

El síndrome de Angelman es un trastorno neurológico genético con características que incluyen retraso en el desarrollo, discapacidad intelectual, deterioro grave del habla y problemas de movimiento y equilibrio. En el presente documento se proporcionan polinucleótidos, vectores, polipéptidos, células, composiciones, kits y métodos para tratar el síndrome de Angelman.
MX2022002139A 2019-08-22 2020-08-21 Ube3a para el tratamiento del sindrome de angelman. MX2022002139A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890364P 2019-08-22 2019-08-22
US201962945062P 2019-12-06 2019-12-06
PCT/US2020/047505 WO2021035181A1 (en) 2019-08-22 2020-08-21 Ube3a for the treatment of angelman syndrome

Publications (1)

Publication Number Publication Date
MX2022002139A true MX2022002139A (es) 2022-03-17

Family

ID=74660741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002139A MX2022002139A (es) 2019-08-22 2020-08-21 Ube3a para el tratamiento del sindrome de angelman.

Country Status (11)

Country Link
US (1) US20220305098A1 (es)
EP (1) EP4017523A4 (es)
JP (1) JP2022545184A (es)
KR (1) KR20220049568A (es)
CN (1) CN114502190A (es)
AU (1) AU2020334924A1 (es)
BR (1) BR112022003310A2 (es)
CA (1) CA3148870A1 (es)
IL (1) IL290178A (es)
MX (1) MX2022002139A (es)
WO (1) WO2021035181A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112470YA (en) * 2019-05-22 2021-12-30 Univ North Carolina Chapel Hill Ube3a genes and expression cassettes and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268163A1 (en) * 2000-06-01 2001-12-11 Genaissance Pharmaceuticals, Inc. Haplotypes of the ube3a gene
US20140298494A1 (en) * 2011-07-25 2014-10-02 Beth Israel Deaconess Medical Center, Inc. Animal model of autism
JP6841507B2 (ja) * 2015-05-07 2021-03-10 ユニヴァーシティ オブ サウス フロリダ アンジェルマン症候群の遺伝子治療法のための組み換えｕｂｅ３ａ遺伝子
CA3036524A1 (en) * 2016-09-09 2018-03-15 Valerion Therapeutics, Llc Methods and compositions for treatment of lafora disease

Also Published As

Publication number Publication date
EP4017523A4 (en) 2024-01-17
CN114502190A (zh) 2022-05-13
US20220305098A1 (en) 2022-09-29
KR20220049568A (ko) 2022-04-21
WO2021035181A1 (en) 2021-02-25
EP4017523A1 (en) 2022-06-29
AU2020334924A1 (en) 2022-04-07
IL290178A (en) 2022-03-01
CA3148870A1 (en) 2021-02-25
BR112022003310A2 (pt) 2022-08-09
JP2022545184A (ja) 2022-10-26

Similar Documents

Publication Publication Date Title
MX2021012461A (es) Procesos para preparar y usar un secretoma derivado de células madre mesenquimales.
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
PH12020551463A1 (en) Pd-1 agonist antibodies and uses thereof.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
MX2021010916A (es) Inhibidores rad51.
WO2019118518A3 (en) Inducible cell receptors for cell-based therapeutics
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
WO2018146679A3 (en) Photoreceptor cells for the treatment of retinal diseases
MX2022002139A (es) Ube3a para el tratamiento del sindrome de angelman.
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2021011622A (es) Células t específicas de antígeno de multiples virus respiratorios y métodos para elaborar y usar las mismas de manera terapéutica.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
WO2023086428A3 (en) Novel modulators of the aryl hydrocarbon receptor and methods of use thereof
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
WO2020092743A3 (en) Methods of treating diseases using kinase modulators
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2021001292A (es) Metodos para la modificacion genica de celulas hematopoyeticas.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof